Hepatitis C virus infection and increased risk of cerebrovascular disease

Stroke

Volumn 41, Issue 12, 2010, Pages 2894-2900

  Lee, Mei Hsuan ^a,b   Yang, Hwai I ^b   Wang, Chih Hao ^c   Jen, Chin Lan ^b   Yeh, Shiou Hwei ^a   Liu, Chun Jen ^d   You, San Lin ^b   Chen, Wei J ^a   Chen, Chien Jen ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cerebrovascular disease; hepatitis C virus; prospective study

Indexed keywords

VIRUS ANTIBODY; VIRUS RNA;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CEREBROVASCULAR DISEASE; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COHORT ANALYSIS; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENOTYPE; HAZARD RATIO; HEPATITIS C; HUMAN; HYPERTENSION; INTERVIEW; LIFESTYLE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SEROLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIBODIES, VIRAL; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL;

EID: 78650419996     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.598136     Document Type: Article

References (37)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
2. Gumber SC, Chopra S. Hepatitis C: A multifaceted disease: review of extrahepatic manifestations. Ann Intern Med. 1995;123:615-620.
3. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-1313.
4. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis b or hepatitis C infection: a large community-based linkage study. Lancet. 2006;368:938-945.
5. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997;349:1269-1276.
6. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack- a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke- co-sponsored by the Council on Cardiovascular Radiology and Intervention- the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617. (Pubitemid 43732031)
7. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol. 1998;148:937-948.
8. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
9. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. JAMA. 2003;289: 1245-1246.
10. Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet. 2002;359: 133-135.
11. Ishizaka Y, Ishizaka N, Takahashi E, Unuma T, Tooda EI, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J. 2003;67:26-30.
12. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myo-cardial infarction and stroke in older adults. N Engl J Med. 1999;340: 14-22.
13. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. 2007;46:1350-1356.
14. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis b virus DNA level. JAMA. 2006; 295:65-73.
15. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Chen CJ. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921-931.
16. Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chew CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496-504.
17. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, Huang WL, Lu SF, Jih J, Chen DS, Chen PJ. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol. 2004;41:659-666.
18. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ. Metabolic factors and risk of hepato-cellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111-121.
19. Fwu CW, Chien YC, Nelson KE, Kirk GD, You SL, Kuo HS, Feinleib M, Chen CJ. Mortality after chronic hepatitis B virus infection: a linkage study involving 2 million parous women from Taiwan. J Infect Dis. 2010;201:1016-1023.
20. Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I, Deurenberg P, Deurenberg-Yap M, Gill T, James P, Ko G, Miu AH, Kosulwat V, Kumanyika S, Kurpad A, Mascie-Taylor N, Moon HK, Nishida C, Noor MI, Reddy KS, Rush E, Schultz JT, Seidell J, Stevens J, Swinburn B, Tan K, Weisell R, Wu ZS, Yajnik CS, Yoshiike N, Zimmet P; WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363: 157-163.
21. Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, Tran J, Weston SR, Kobashigawa J. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2:443-447.
22. Younossi ZM, Braun WE, Protiva DA, Gifford RW, Straffon RA. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation. 1999;67:272-275.
23. Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, Busch MP, Murphy EL. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol. 2008;167:743-750.
24. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis. 2006;43:E53-E56.
25. Volzke H, Schwahn C, Wolff B, Mentel R, Robinson DM, Kleine V, Felix SB, John U. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis. 2004;174: 99-103.
26. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu QB, Wick G, Poewe W, Willeit J. Chronic infections and the risk of carotid atherosclerosis- prospective results from a large population study. Circulation. 2001;103:1064-1070.
27. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002; 33:2581-2586. (Pubitemid 35266427)
28. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
29. Hansson GK. Mechanisms of disease- inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
30. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in us veterans with hepatitis C virus. JAMA. 2007;297: 2010-2017.
31. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis. 2005;5: 227-236.
32. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610. (Pubitemid 39628581)
33. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007. (Pubitemid 41262334)
34. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166:196-203.
35. Marchioni E, Ceroni M, Erbetta A, Alfonsi E, Bottanelli M, Imbesi F, Ricevuti G. Severe acute cerebrovascular disease revealing hepatitis C virus infection: effectiveness of alpha-interferon. J Neurol. 2002;249: 1111-1113.
36. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001;358:38-39.
37. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat. 2003;10:81-86.